News Novo, Lilly trade oral GLP-1 data readouts at ECO Novo Nordisk trumpets oral Wegovy efficacy data at ECO, while Lilly builds the case for switching to Foundayo in maintenance phase after injectables.
News Boehringer, Brainomix plan new trial of lung fibrosis AI Boehringer and Brainomix are planning a prospective trial of an AI to diagnose pulmonary fibrosis, after positive results in an observational study.
News Novo says high-dose Wegovy can cause 28% weight loss Novo Nordisk has built the case for migration to its 'triple-dose' version of injectable GLP-1 Wegovy with new weight-loss and body composition data.
R&D On the ICH E20 draft guideline (2025) for adaptive clinical ... A review of the scope, key principles, methodological expectations, and regulatory implications of ICH E20.
News Novo Nordisk microRNA drug fluffs its lines in heart failure A microRNA-targeting drug acquired by Novo Nordisk when it bought Cardior in a $1bn-plus deal has generated disappointing results in heart failure.
News Bayer plans filings for cardiac amyloidosis imaging agent Armed with new phase 3 data, Bayer is preparing to file a PET imaging agent that could accelerate the diagnosis of cardiac amyloidosis.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.